Related Experiment Video
Updated: Apr 12, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Immunotherapeutic approaches in prostate cancer: combinations and clinical integration
1From the Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY.
Abstract:
Despite multiple immunologic approaches with peptide, protein, and DNA vaccines, no single therapy has induced complete remission or maintained durability of response in patients with castration-resistant prostate cancer (CRPC). Historically, immunotherapy has had limited effect on solid tumors with the exception of melanoma and renal cell carcinomas, which have been deemed as immunologic cancers given their potential for remissions either spontaneously or after removal of the primary lesion. There is considerable excitement about using an immunotherapy in combination with biologic agents such as checkpoint inhibitors, cytokines, other vaccines, or chemotherapy. Sipuleucel-T represents one of several novel immunologic therapeutic approaches to treat prostate cancer in addition to other solid tumors. It is the first in its class of autologous cellular therapies to demonstrate safety and an overall survival benefit in patients with asymptomatic or minimally symptomatic CRPC and represents a unique treatment method that may be further enhanced with other agents. Although sipuleucel-T can be used as a foundation on which to build and enhance future immunologic clinical trials, other exciting strategies are in development that may be easily integrated into the algorithm of current care.
Insights
Sipuleucel-T is a novel immunotherapy for castration-resistant prostate cancer (CRPC). This autologous cellular therapy is the first to show safety and survival benefits in CRPC patients.
Area of Science:
- Oncology
- Immunotherapy
- Prostate Cancer Research
Background:
- Castration-resistant prostate cancer (CRPC) has limited treatment options, with no single immunotherapy achieving complete remission.
- Immunotherapy has historically shown limited efficacy in solid tumors, unlike melanoma and renal cell carcinoma.
- Combination therapies involving immunotherapy with other agents are a promising area of research.
Purpose of the Study:
- To evaluate Sipuleucel-T as a novel immunologic therapeutic approach for prostate cancer.
- To assess the safety and overall survival benefit of Sipuleucel-T in CRPC patients.
- To explore Sipuleucel-T's potential as a foundational therapy for future immunologic trials.
Main Methods:
- Sipuleucel-T, an autologous cellular therapy, was administered to patients with asymptomatic or minimally symptomatic CRPC.
- Clinical trials assessed safety and overall survival outcomes.
- Exploration of Sipuleucel-T's integration with other therapeutic agents.
Main Results:
- Sipuleucel-T demonstrated safety and an overall survival benefit in the target patient population.
- It represents a unique treatment method for CRPC.
- The therapy showed potential for enhancement with other agents.
Conclusions:
- Sipuleucel-T is the first autologous cellular therapy to show a survival benefit in CRPC.
- It offers a new treatment option and can serve as a basis for future immunologic studies in prostate cancer.
- Further integration with other therapies may enhance its efficacy.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...